Millions of breast cancer patients could be spared the ‘physical and emotional burden’ of chemotherapy thanks to a groundbreaking gene test.
The test, called Prosigna, measures the activity of genes involved in breast cancer growth.
A study that followed more than 4,400 patients aged 40 and over across the UK, Norway, Sweden, Australia, New Zealand and Thailand found chemotherapy had ‘little or no additional benefit’ to people whose tumours had a low Prosigna test score.
It found more than two-thirds of those who took part in the study could be safely treated with hormone therapy alone.
The trial led by University College London (UCL) was designed to find out
To provide well-rounded coverage and a breadth of insight across various events, we rely on contributions from several staff writers, each bringing their own area of expertise to our publication.
